What is it about?
Thyroid nodules rank as one of the most prevalent endocrine discoveries, with fine-needle aspiration cytology (FNAC) serving as the primary minimally invasive method for their assessment. Despite the recent 2023 revision of the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), which has established standardized terminology and malignancy-risk assessments, a significant number of aspirates continue to be classified as indeterminate specifically atypia of undetermined significance (Bethesda III), follicular neoplasm (Bethesda IV), and suspicious for malignancy (Bethesda V). These classifications possess intersecting nuclear, architectural, cytoplasmic, and contextual characteristics that constrain the distinguishing capability of any individual morphological standard.
Featured Image
Why is it important?
Thyroid nodules are among the most commonly observed irregularities in endocrine medicine, and their identified occurrence is increasing due to the extensive application of high-resolution ultrasonography and cross-sectional imaging. Over 95% of thyroid nodules are non-cancerous; nevertheless, differentiating between benign and malignant lesions is difficult due to similarities in their physical and cytological characteristics and significant biological variability. FNAC serves as the fundamental assessment for thyroid nodules due to its minimally invasive nature, cost efficiency, speed, and direct influence on clinical decision-making, thereby minimizing unnecessary surgical interventions [1-2]. The primary constraint occurs when cytological characteristics lack adequate differentiation for a conclusive diagnosis, leading to a cytological "grey zone" that includes lesions exhibiting a mix of benign, borderline, and malignant traits, along with significant inter-observer heterogeneity. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was established in 2010 and updated in 2017 to create a standardized six-tier reporting framework. The 2023 third edition enhanced diagnostic terminology and malignancy-risk estimates by aligning with the 2022 WHO classification of thyroid neoplasms, reclassifying atypia of undetermined significance (AUS), and broadening recommendations for ancillary and molecular testing. Morphology continues to serve as the foundation for cytological analysis, and nuanced nuclear anomalies, chromatin modifications, cytoplasmic characteristics, and contextual indicators may provide diagnostic insights that are overlooked when evaluating features independently. This critique suggests a systematic methodology, the Cytological Grey-Zone Morphological Signature (CGZ-MS) framework, for methodically identifying these "hidden" morphological markers and correlating them with histopathological, molecular, and clinical results
Perspectives
The cytological grey zone of indeterminate thyroid FNAC should not be viewed only as a realm of diagnostic ambiguity but as a biologically heterogeneous morphological spectrum in which clinically relevant information may be hidden within nuanced, localised and interrelated cytological features. Systematic mapping of nuclear, architectural, cytoplasmic, background and stromal signals offers a conceptual route for converting descriptive atypia into organised morphological phenotypes. Combining these signatures with the standardised lexicon and risk framework of the 2023 Bethesda System, ultrasound findings, clinical data, histopathological correlation and judiciously selected ancillary or molecular testing could improve diagnostic clarity in Bethesda III–V lesions. The proposed CGZ-MS framework offers a potential foundation for quantitative assessment, inter-observer comparison, digital cytology and AI-assisted morphological analysis; its clinical relevance, however, depends entirely on prospective, multicentre validation. The framework is intended to complement, not replace, expert cyto-pathological assessment and the established Bethesda classification, by systematically identifying composite morphological markers and their biological associations — ultimately working toward a more personalised, evidence-based approach to malignancy-risk assessment in the thyroid cytological grey zone.
Dr Ajit Pal Singh
Sharda University
Read the Original
This page is a summary of: The Cytological Grey Zone: Mapping Concealed Morphological Signatures in Indeterminate Thyroid Fine-Needle Aspiration Cytology, International Journal of Research and Scientific Innovation, January 2026, International Journal of Research and Innovation in Social Science,
DOI: 10.51244/ijrsi.2026.1309000059.
You can read the full text:
Contributors
The following have contributed to this page
